2023年12月最新中科院分区表数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。基本信息 | 登录收藏 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | OncoTargets and Therapy ONCOTARGETS THER (此期刊被最新的JCR期刊SCIE收录) LetPub评分 4.9
52人评分
我要评分
声誉 3.5 影响力 5.2 速度 9.2 | |||||||||||||||||||||
期刊ISSN | 1178-6930 | 微信扫码收藏此期刊 | ||||||||||||||||||||
2022-2023最新影响因子 (数据来源于搜索引擎) | 4 点击查看影响因子趋势图 | |||||||||||||||||||||
实时影响因子 | 截止2024年3月26日:2.612 | |||||||||||||||||||||
2022-2023自引率 | 0.00%点击查看自引率趋势图 | |||||||||||||||||||||
五年影响因子 | 3.7 | |||||||||||||||||||||
h-index | 44 | |||||||||||||||||||||
CiteScore |
| |||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||
期刊官方网站 | https://www.dovepress.com/oncotargets-and-therapy-journal | |||||||||||||||||||||
期刊投稿网址 | https://www.dovepress.com/submit_step_1.php | |||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足OncoTargets and Therapy的语言要求,还能让OncoTargets and Therapy编辑和审稿人得到更好的审稿体验,让稿件最大限度地被OncoTargets and Therapy编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
是否OA开放访问 | Yes | |||||||||||||||||||||
OA期刊相关信息 | 文章处理费:需要( USD2310; ) 文章处理费豁免:查看说明 其他费用:没有 期刊主题关键词:oncology、cancer、palliative care、therapeutic agents 相关链接:Aims & ScopeAuthor InstructionsEditorial BoardBlind peer review | |||||||||||||||||||||
通讯方式 | PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752 | |||||||||||||||||||||
出版商 | Dove Medical Press Ltd. | |||||||||||||||||||||
涉及的研究方向 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY | |||||||||||||||||||||
出版国家或地区 | ENGLAND | |||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||
出版周期 | ||||||||||||||||||||||
出版年份 | 2008 | |||||||||||||||||||||
年文章数 | 124点击查看年文章数趋势图 | |||||||||||||||||||||
Gold OA文章占比 | 97.88% | |||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 63.71% | |||||||||||||||||||||
WOS期刊SCI分区 ( 2022-2023年最新版) | WOS分区等级:2区
| |||||||||||||||||||||
中科院《国际期刊预警 名单(试行)》名单 | 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:预警等级:中 2020年12月发布的2020版:预警等级:中 | |||||||||||||||||||||
中科院SCI期刊分区 ( 2023年12月最新升级版) | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
中科院SCI期刊分区 ( 2022年12月升级版) |
| |||||||||||||||||||||
中科院SCI期刊分区 ( 2021年12月旧的升级版) |
| |||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1178-6930%5BISSN%5D | |||||||||||||||||||||
平均审稿速度 | 网友分享经验: 较慢,6-12周 | |||||||||||||||||||||
平均录用比例 | 网友分享经验: 较易 | |||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在OncoTargets and Therapy顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 | |||||||||||||||||||||
期刊常用信息链接 |
|
|
|
中国学者近期发表的论文 | |
1. | Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report Author: Zhang, Xiangming; Ni, Kai; Chen, Huijun Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 87-90. DOI: 10.2147/OTT.S393165 PubMed DOI |
2. | Role of Systemic Immunoinflammation Landscape in the Overall Survival of Patients with Leptomeningeal Metastases from Lung Cancer Author: Wang, Jia-Wei; Yuan, Qing; Li, Li; Cao, Kai-Hua; Liu, Qi; Wang, Hong-Liang; Hu, Ke; Wu, Xi; Wan, Jing-Hai Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 179-187. DOI: 10.2147/OTT.S402389 PubMed DOI |
3. | Secondary Sinonasal Collision Tumor of Papillary Squamous Cell Carcinoma and Small Cell Neuroendocrine Carcinoma After Nasopharyngeal Carcinoma Radiotherapy: A Case Report and Literature Review of Sinonasal Collision Carcinomas Author: Tang, Hao; Wang, Lina; Xu, Wenfeng; Xu, Yujuan; Li, Xianyun; Guo, Deyu Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 91-97. DOI: 10.2147/OTT.S396703 PubMed DOI |
4. | Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK-LIMS1 Fusion: A Case Report Author: Shi, Junmei; Jia, Zhaohui; Zhou, Zhiguo; Zhao, Liyan; Meng, Qingju; Liu, Yibing Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 109-114. DOI: 10.2147/OTT.S388962 PubMed DOI |
5. | Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study Author: Li, Guiling; Cheng, Mingxia; Hong, Kai; Jiang, Yao Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 157-163. DOI: 10.2147/OTT.S400376 PubMed DOI |
6. | A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review Author: Li, Dan; Liu, Xin; Cui, SaiQiong; Yang, DaFu; Zhu, Yue; Pan, Evenki; Yang, Peng; Dai, ZhaoXia Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 17-22. DOI: 10.2147/OTT.S391766 PubMed DOI |
7. | Transmission of Exosomal TPX2 Promotes Metastasis and Resistance of NSCLC Cells to Docetaxel Author: Hu, Jiaru; He, Qing; Tian, Tian; Chang, Na; Qian, Liting Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 197-210. DOI: 10.2147/OTT.S401454 PubMed DOI |
8. | A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib Author: Fan, Weiming; Wang, Chuan; Zhong, Xuefeng; Zheng, Yating; Chen, Tingting; Huang, Mengli; Su, Shuying Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 23-29. DOI: 10.2147/OTT.S390458 PubMed DOI |
9. | Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma. Author: Zou Y1, Zhou J1, Xu B1, Li W1, Wang Z1. Journal: Onco Targets Ther. 2019 Apr 30;12:3267-3275. doi: 10.2147/OTT.S196347. eCollection 2019. PubMed DOI |
10. | MEX3C regulates lipid metabolism to promote bladder tumorigenesis through JNK pathway. Author: Chao H1, Deng L2, Xu F3, Yu Z2, Xu X2, Huang J2, Zeng T4. Journal: Onco Targets Ther. 2019 May 1;12:3285-3294. doi: 10.2147/OTT.S199667. eCollection 2019. PubMed DOI |
|
|
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分: | |
同领域作者分享投稿经验:共1243条 (包含回复) |
我来分享 |
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海分公司 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960
增值电信业务经营许可证:沪B2-20211595
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451